跳至主要内容
临床试验/NCT04455243
NCT04455243Unknown3 期

Pilot Double Blinded Randomized Placebo Controlled Multi Central Clinical Trial on Inflammatory Regulation Effect of NAC on COVID-19

Dr. Tariq Alhawassi0 个研究点目标入组 1,180 人开始时间: 2020年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
发起方
入组人数
1,180
主要终点
Time to Recovery

研究概览

简要总结

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult above 18 years of age
  • Admitted to the hospital With confirmed COVID-19 by RT-PCR test
  • On oxygen supplement

排除标准

  • Active use of NAC
  • Known NAC allergy
  • In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment
  • All patients enrolled in any other investigational drug studies in COVID-19.

研究组 & 干预措施

Intervention group

Experimental

干预措施: N-Acetyl cysteine (Drug)

Control group

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Time to Recovery

时间窗: 28 days

Day of recovery is defined as the first day on which of the following three categories from The Ordinal Scale on Covid-19 Clinical Improvement 1. Not-Hospitalized, No limitation on activity. 2. Not Hospitalized, with limitation on activity. 3. Hospitalized, Not requiring supplemental Oxygen

次要结局

未报告次要终点

研究者

发起方
Dr. Tariq Alhawassi
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Dr. Tariq Alhawassi

Chairman of Clinical Trial Support Unit

King Saud University

相似试验